Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.25 (-1.79%)
Spread: 0.50 (3.704%)
Open: 14.00
High: 14.00
Low: 13.75
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics - New Venture Co.

6 May 2005 07:00

Angle PLC06 May 2005 For Immediate Release 6 May 2005 ANGLE plc GEOMERICS: NEW VENTURE COMPANY ANGLE plc ("ANGLE"), the venture management and consulting company specialisingin the commercialisation of technology, is pleased to announce the launch of itslatest venture company, Geomerics Ltd ('Geomerics'). Geomerics has secured intellectual property in the field of geometric algebra.Geometric Algebra is a powerful new form of mathematics that vastly simplifiescomplex geometric calculations. Geometric Algebra has its origins in the ratheresoteric academic discipline of theoretical cosmology, but it has now beendeveloped for application in a wide variety of disparate commercial applicationssuch as computer graphics in computer games and electromagnetic modelling whichis used, amongst other things, for optimising the design of mobile phoneantennas and reducing the radar signature of ships and planes. One of the main differentiators between computer games is the speed and qualityof rendering of the graphics. With best-selling games generating severalhundred million dollars for their developers, the quest for better and fastergraphics engines is relentless. Geomerics' technology provides a step-changeimprovement over the competition, and is set to revolutionise the market.Overall the market for computer games is currently worth more than $30bn andgrowing rapidly, and the market for graphics within these games is worth over$600m per year. Current electromagnetic modelling techniques do not give the accuracy requiredin many applications, because the processing power required is prohibitive.Geomerics' technology has already been used to resolve complex electromagneticmodelling problems that rival systems have been unable to solve. Theelectromagnetic modelling market is worth in excess of $100m per year and thereis also considerable latent demand. This new approach in applying geometric algebra has been developed by a group offour leading academics from the University of Cambridge: Professor AnthonyLasenby (Professor of Astrophysics and Cosmology), Dr Mike Hobson (UniversityReader in Astrophysics), Dr Chris Doran (EPSRC Advanced Research Fellow) and DrJoan Lasenby (Lecturer in Engineering). Geomerics has also engaged ProfessorDavid Hestenes of Arizona State University (the original inventor of geometricalgebra) and Professor Alyn Rockwood of Colorado School of Mines (a geometricalgebra and computer graphics expert) in an advisory capacity. In accordance with ANGLE's Progeny(R) process for creating new ventures, ANGLE'splan is to build a strong commercial offering in each of the key marketssequentially, seeking a return on its investment in the medium term.Simultaneously, development work will continue on the geometric algebraplatform. ANGLE expects to spend up to £500,000 in the Progeny(R) venture, whichis presently wholly owned by ANGLE. Commenting on the collaboration with ANGLE, Professor Lasenby said: 'We have been developing the mathematics and technology behind Geomerics for anumber of years, and now is the perfect time to apply it to commercialapplications. We are delighted that ANGLE will be commercialising ourtechnology.' ANGLE's Chief Executive Andrew Newland said: 'Computer graphics and electromagnetic modelling are large, growing markets.Geomerics' technology is truly leading-edge and we believe it will revolutionisea wide range of fields. We are delighted to be working with such a high calibreof academic inventors.' For further information: ANGLE plcAndrew Newland, Chief Executive 01483 295830Stephen Bence, Associate Director - Ventures UK 01223 472745 Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Dec 20199:55 amRNSIssue of Equity
7th Nov 20197:00 amRNSCancer centre shows Parsortix use in melanoma
30th Oct 20192:44 pmRNSResult of AGM
30th Oct 20197:00 amRNSQ-submission to FDA containing headline data
8th Oct 20197:00 amRNSNotice of AGM
4th Oct 20195:54 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSEuropean patent granted for megakaryocyte analysis
13th Sep 20197:00 amRNSUse of Parsortix in head and neck cancer
10th Sep 20197:00 amRNSResearch with Parsortix in prostate cancer
4th Sep 20197:00 amRNSParsortix for Neuroendocrine Analysis in SCLC
29th Aug 20197:00 amRNSInitiation of Ovarian Cancer Study
31st Jul 20197:00 amRNSPrelim Results for the year ended 30 April 2019
22nd Jul 20197:00 amRNSUse of Parsortix for single cell analysis of CTCs
16th Jul 20199:19 amRNSHolding(s) in Company
12th Jul 201910:22 amRNSResult of General Meeting anf Total Voting Rights
28th Jun 20191:37 pmRNSNotice of Preliminary Results and Webcast
28th Jun 20191:08 pmRNSHolding(s) in Company
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension
1st Nov 20187:00 amRNSAppointment of Dr Jan Groen as NED
30th Oct 20184:21 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.